AVITENE MICROFIBRILLAR COLLAGEN HEMOSTAT NON-WOVEN WEB
C.R. Bard, Inc. · Decision date Oct 24, 1980
What did the FDA approve?
FDA records P800002 as an original PMA application. The recorded decision is approval, dated Oct 24, 1980.
An approval order statement is not included in the imported record. Open the FDA listing for the decision documents.
- Regulatory pathway
- Original PMA
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Oct 24, 1980
Regulatory record facts
- Identifier
- P800002
- Regulatory pathway
- Premarket approval application
- Applicant
- C.R. Bard, Inc.
- Product code
- LMF
- Decision code
- APPR
- Decision date
- Oct 24, 1980
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, collagen based.
- Applicant
- C.R. Bard, Inc.
- Product code
- LMF
- FDA device class
- 3
FDA decision timeline
P800002 received
Application receipt date recorded by FDA.
P800002 · FDA decision
APPR
P800002/S036 · Related supplement
Avitene Microfibrillar Collagen Hemostat (MCH) Non-Woven Web Webber
Timeline entries are records held by MedtechLedger for P800002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P800002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| C.R. Bard, Inc. | PMA supplement | Sep 29, 2026 | FDA |
Explore the linked device profile
Other records with product code LMF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA | |
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA | |
SURGIFOAM Absorbable Gelatin SpongeP990004/S080 | Ferrosan Meidcal Devices A/S | PMA supplement | Sep 18, 2026 | FDA |
| Ferrosan Meidcal Devices A/S | PMA approval | Sep 30, 1999 | FDA | |
| Integra LifeSciences Corporation | PMA approval | Nov 8, 1985 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
C.R. Bard, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 160 New Boston St., Woburn, MA, 01801
Sources and methodology
- Original FDA record: P800002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
